Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Mon, August 4, 2025 at 11:15 AM UTC Viking Therapeutics (NASDAQ: VKTX) represents exactly this type of overlooked opportunity, trading at a valuation of just $3.7 billion as of Aug. 1, despite owning ...

Alumis Inc., a San Francisco-based biotech, completed its IPO in June last year, raising ~$250m, and focuses on developing TYK2 inhibitors ESK-001 and A-005. Alumis' ESK-001 is in Phase 3 trials for ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...

Shares of IO Biotech, Inc. IOBT are plummeting Tuesday after the company announced it filed for Chapter 7 bankruptcy and will ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...